Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Lorundrostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 247,857Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mineralys Therapeutics Announces Late-Breaking Data Presentation
    Mineralys Therapeutics Announces Late-Breaking Data Presentation

    24 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/24/3087776/0/en/Mineralys-Therapeutics-Announces-Late-Breaking-Presentation-of-Data-from-the-Launch-HTN-Pivotal-Trial-of-Lorundrostat-in-Uncontrolled-or-Resistant-Hypertension-at-34th-European-Mee.html

    GLOBENEWSWIRE
    24 May 2025
    Share Share
    Mineralys Therapeutics Announces Ph 2 Advance-HTN Results in NEJM
    Mineralys Therapeutics Announces Ph 2 Advance-HTN Results in NEJM

    23 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066971/0/en/Mineralys-Therapeutics-Announces-Publication-of-Pivotal-Phase-2-Advance-HTN-Results-in-the-New-England-Journal-of-Medicine-NEJM.html

    GLOBENEWSWIRE
    23 Apr 2025
    Share Share
    Mineralys Reports Late-Breaking Data From Advance-HTN Trial
    Mineralys Reports Late-Breaking Data From Advance-HTN Trial

    29 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/29/3051760/0/en/Mineralys-Therapeutics-Announces-Late-Breaking-Data-from-Advance-HTN-Pivotal-Trial-of-Lorundrostat-in-Uncontrolled-and-Resistant-Hypertension-Presented-at-the-American-College-of-C.html

    GLOBENEWSWIRE
    29 Mar 2025
    Share Share
    Mineralys Reports Positive Ph3 Lorundrostat Data In Hypertension
    Mineralys Reports Positive Ph3 Lorundrostat Data In Hypertension

    10 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/10/3039559/0/en/Mineralys-Therapeutics-Announces-Positive-Topline-Results-from-Launch-HTN-and-Advance-HTN-Pivotal-Trials-of-Lorundrostat-for-the-Treatment-of-Uncontrolled-or-Resistant-Hypertension.html

    GLOBENEWSWIRE
    10 Mar 2025
    Share Share
    Mineralys Completes Enrollment in Explore-CKD Ph 2 for Hypertension
    Mineralys Completes Enrollment in Explore-CKD Ph 2 for Hypertension

    04 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/04/3020225/0/en/Mineralys-Therapeutics-Completes-Enrollment-in-Explore-CKD-Phase-2-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension-in-Subjects-with-Stage-2-to-3b-CKD-and-Albuminuria.html

    GLOBENEWSWIRE
    04 Feb 2025
    Share Share
    Mineralys Completes Enrollment in Lorundrostat Hypertension Trial
    Mineralys Completes Enrollment in Lorundrostat Hypertension Trial

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971654/0/en/Mineralys-Therapeutics-Completes-Enrollment-Ahead-of-Schedule-in-Launch-HTN-the-Second-Pivotal-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share